Fluorescent diagnosis and photodynamic therapy for C6 glioma in combination with antiangiogenic therapy in subcutaneous and intracranial tumor models

Fluorescent diagnosis and photodynamic therapy for C6 glioma in combination with antiangiogenic therapy in subcutaneous and intracranial tumor models

Objective: Investigating the distinctions pharmacokinetics of chlorin e6 conjugated with polyvinyl pyrrolidone photosensitizer (Ce6CPPPS)in healthy and tumor tissues of rat brain and evaluating the antitumor efficacy of combination treatment for C6 rat glioma including photodynamic (PDT) and antiang...

Повний опис

Збережено в:
Бібліографічні деталі
Дата:2014
Автори: Tzerkovsky, D.A., Osharin, V.V., Istomin, Y.P., Alexandrova, E.N., Vozmitel, M.A.
Формат: Стаття
Мова:English
Опубліковано: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2014
Назва видання:Experimental Oncology
Теми:
Original contributions
Онлайн доступ:http://dspace.nbuv.gov.ua/handle/123456789/145336
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
Назва журналу:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Цитувати:Fluorescent diagnosis and photodynamic therapy for C6 glioma in combination with antiangiogenic therapy in subcutaneous and intracranial tumor models / D.A. Tzerkovsky, V.V. Osharin, Y.P. Istomin, E.N. Alexandrova, M.A. Vozmitel // Experimental Oncology. — 2014. — Т. 36, № 2. — С. 85-89. — Бібліогр.: 27 назв. — англ.

Репозитарії

Digital Library of Periodicals of National Academy of Sciences of Ukraine
id irk-123456789-145336
record_format dspace
fulltext
spelling irk-123456789-1453362019-01-21T01:24:12Z Fluorescent diagnosis and photodynamic therapy for C6 glioma in combination with antiangiogenic therapy in subcutaneous and intracranial tumor models Tzerkovsky, D.A. Osharin, V.V. Istomin, Y.P. Alexandrova, E.N. Vozmitel, M.A. Original contributions Objective: Investigating the distinctions pharmacokinetics of chlorin e6 conjugated with polyvinyl pyrrolidone photosensitizer (Ce6CPPPS)in healthy and tumor tissues of rat brain and evaluating the antitumor efficacy of combination treatment for C6 rat glioma including photodynamic (PDT) and antiangiogenic therapy (AAT). Materials and Methods: The study was performed on 50 white random-bred rats in subcutaneous and intracranial models of C6 glioma. Photosensitizer (PS) Ce6CPPPS single injection at a dose of 2.5 mg/kg was made into the animal’s caudal vein. The PS accumulation level in brain tissues and C6 rat glioma was measured with spectral fluorescence technique using LESA-01-Biospek spectrum analyser (Russian Federation, Moscow; λ = 632.8 nm). Photoirradiation of intracranial and subcutaneous C6 glioma was carried out with a light exposure dose of 50 J/cm2 (IMAF-Axicon, Republic of Belarus; λ = 661 nm). AAT drug bevacizumab, single injection was made intravenously at a dose of 10 mg/kg 24 h after tumor photoirradiation. The criteria for efficacy evaluation were mean survival time (MST) and median survival of the animals in the study group vs the control and the ­percentage of tumor necrosis areas induced by the above-mentioned treatment. Results: The optimal time for photoirradiation of intracranial C6 glioma is 0.5 h after Ce6CPPPS injection. The combination therapy group demonstrated a statistically significant MST increase (38.4 ± 4.39 days) compared with the PDT group (29.2 ± 3.5 days) (p = 0.02) and the AAT group (27.1 ± 2.74 days) (p = 0.02). Necrosis areas in tumor tissue were as follows: the intact control — 10.0 ± 2.55%, PDT — 54.87 ± 6.95% (p = 0.003), AAT — 57.83 ± 6.53% (p = 0.003) and combination therapy — 89.43 ± 5.57% (p = 0.001). Conclusions: This paper is the first report about feasibility of efficient use of PDT with a PS of chlorin series and AAT with bevacizumab for the treatment of brain tumors in experimental models. Key Words: Ce6CPPPS, bevacizumab, glioma C6, photodynamic therapy, antiangiogenic therapy. 2014 Article Fluorescent diagnosis and photodynamic therapy for C6 glioma in combination with antiangiogenic therapy in subcutaneous and intracranial tumor models / D.A. Tzerkovsky, V.V. Osharin, Y.P. Istomin, E.N. Alexandrova, M.A. Vozmitel // Experimental Oncology. — 2014. — Т. 36, № 2. — С. 85-89. — Бібліогр.: 27 назв. — англ. 1812-9269 http://dspace.nbuv.gov.ua/handle/123456789/145336 en Experimental Oncology Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
language English
topic Original contributions
Original contributions
spellingShingle Original contributions
Original contributions
Tzerkovsky, D.A.
Osharin, V.V.
Istomin, Y.P.
Alexandrova, E.N.
Vozmitel, M.A.
Fluorescent diagnosis and photodynamic therapy for C6 glioma in combination with antiangiogenic therapy in subcutaneous and intracranial tumor models
Experimental Oncology
description Objective: Investigating the distinctions pharmacokinetics of chlorin e6 conjugated with polyvinyl pyrrolidone photosensitizer (Ce6CPPPS)in healthy and tumor tissues of rat brain and evaluating the antitumor efficacy of combination treatment for C6 rat glioma including photodynamic (PDT) and antiangiogenic therapy (AAT). Materials and Methods: The study was performed on 50 white random-bred rats in subcutaneous and intracranial models of C6 glioma. Photosensitizer (PS) Ce6CPPPS single injection at a dose of 2.5 mg/kg was made into the animal’s caudal vein. The PS accumulation level in brain tissues and C6 rat glioma was measured with spectral fluorescence technique using LESA-01-Biospek spectrum analyser (Russian Federation, Moscow; λ = 632.8 nm). Photoirradiation of intracranial and subcutaneous C6 glioma was carried out with a light exposure dose of 50 J/cm2 (IMAF-Axicon, Republic of Belarus; λ = 661 nm). AAT drug bevacizumab, single injection was made intravenously at a dose of 10 mg/kg 24 h after tumor photoirradiation. The criteria for efficacy evaluation were mean survival time (MST) and median survival of the animals in the study group vs the control and the ­percentage of tumor necrosis areas induced by the above-mentioned treatment. Results: The optimal time for photoirradiation of intracranial C6 glioma is 0.5 h after Ce6CPPPS injection. The combination therapy group demonstrated a statistically significant MST increase (38.4 ± 4.39 days) compared with the PDT group (29.2 ± 3.5 days) (p = 0.02) and the AAT group (27.1 ± 2.74 days) (p = 0.02). Necrosis areas in tumor tissue were as follows: the intact control — 10.0 ± 2.55%, PDT — 54.87 ± 6.95% (p = 0.003), AAT — 57.83 ± 6.53% (p = 0.003) and combination therapy — 89.43 ± 5.57% (p = 0.001). Conclusions: This paper is the first report about feasibility of efficient use of PDT with a PS of chlorin series and AAT with bevacizumab for the treatment of brain tumors in experimental models. Key Words: Ce6CPPPS, bevacizumab, glioma C6, photodynamic therapy, antiangiogenic therapy.
format Article
author Tzerkovsky, D.A.
Osharin, V.V.
Istomin, Y.P.
Alexandrova, E.N.
Vozmitel, M.A.
author_facet Tzerkovsky, D.A.
Osharin, V.V.
Istomin, Y.P.
Alexandrova, E.N.
Vozmitel, M.A.
author_sort Tzerkovsky, D.A.
title Fluorescent diagnosis and photodynamic therapy for C6 glioma in combination with antiangiogenic therapy in subcutaneous and intracranial tumor models
title_short Fluorescent diagnosis and photodynamic therapy for C6 glioma in combination with antiangiogenic therapy in subcutaneous and intracranial tumor models
title_full Fluorescent diagnosis and photodynamic therapy for C6 glioma in combination with antiangiogenic therapy in subcutaneous and intracranial tumor models
title_fullStr Fluorescent diagnosis and photodynamic therapy for C6 glioma in combination with antiangiogenic therapy in subcutaneous and intracranial tumor models
title_full_unstemmed Fluorescent diagnosis and photodynamic therapy for C6 glioma in combination with antiangiogenic therapy in subcutaneous and intracranial tumor models
title_sort fluorescent diagnosis and photodynamic therapy for c6 glioma in combination with antiangiogenic therapy in subcutaneous and intracranial tumor models
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
publishDate 2014
topic_facet Original contributions
url http://dspace.nbuv.gov.ua/handle/123456789/145336
citation_txt Fluorescent diagnosis and photodynamic therapy for C6 glioma in combination with antiangiogenic therapy in subcutaneous and intracranial tumor models / D.A. Tzerkovsky, V.V. Osharin, Y.P. Istomin, E.N. Alexandrova, M.A. Vozmitel // Experimental Oncology. — 2014. — Т. 36, № 2. — С. 85-89. — Бібліогр.: 27 назв. — англ.
series Experimental Oncology
work_keys_str_mv AT tzerkovskyda fluorescentdiagnosisandphotodynamictherapyforc6gliomaincombinationwithantiangiogenictherapyinsubcutaneousandintracranialtumormodels
AT osharinvv fluorescentdiagnosisandphotodynamictherapyforc6gliomaincombinationwithantiangiogenictherapyinsubcutaneousandintracranialtumormodels
AT istominyp fluorescentdiagnosisandphotodynamictherapyforc6gliomaincombinationwithantiangiogenictherapyinsubcutaneousandintracranialtumormodels
AT alexandrovaen fluorescentdiagnosisandphotodynamictherapyforc6gliomaincombinationwithantiangiogenictherapyinsubcutaneousandintracranialtumormodels
AT vozmitelma fluorescentdiagnosisandphotodynamictherapyforc6gliomaincombinationwithantiangiogenictherapyinsubcutaneousandintracranialtumormodels
first_indexed 2025-07-10T21:27:31Z
last_indexed 2025-07-10T21:27:31Z
_version_ 1837296886128574464

Схожі ресурси